Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

China's National Medical Products Association Approves AstraZeneca's Fasenra (Benralizumab) For The Maintenance Treatment Of Patients 12 Years And Older With Severe Eosinophilic Asthma

Author: Benzinga Newsdesk | August 20, 2024 04:58am

Posted In: AZN AZNCF

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist